FDA "FLEXIBILITY" IN DETERMINING ACCEPTABLE OTC ORAL ANTISEPTIC RESEARCH PROGRAMS
This article was originally published in The Tan Sheet
Executive Summary
FDA "FLEXIBILITY" IN DETERMINING ACCEPTABLE OTC ORAL ANTISEPTIC RESEARCH PROGRAMS is requested by the Non-prescription Drag Manufacturers Association in Aug. 8 comments on FDA's tentative final monograph on oral antiseptic products. NDMA "requests the agency to adopt a flexible, case-by-case approach when determining the requirements for testing an active ingredient," the comments state.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning